Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Spelman

Showing results (241-250 of 266) with videos related to

Pageof 27
Sort By:
Brain : a Journal of Neurology|September 12, 2015
Defining reliable disability outcomes in multiple sclerosisTomas Kalincik, Gary Cutter, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 6, 2024
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data NetworkJohannes Lorscheider, Alessio Signori, Suvitha Subramaniam, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 28, 2022
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data networkAlessio Signori, Johannes Lorscheider, Sandra Vukusic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 11, 2013
Predictors and dynamics of postpartum relapses in women with multiple sclerosisStella E Hughes, Tim Spelman, Orla M Gray, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2015
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosisMatthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, et al.
Multiple Sclerosis and Related Disorders|August 2, 2022
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-βSteve Simpson-Yap, Ashkan Pirmani, Edward De Brouwer, et al.
Brain : a Journal of Neurology|July 13, 2016
Defining secondary progressive multiple sclerosisJohannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 15, 2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisTomas Kalincik, Eva Kubala Havrdova, Dana Horakova, et al.
Annals of Neurology|October 7, 2014
Seasonal variation of relapse rate in multiple sclerosis is latitude dependentTim Spelman, Orla Gray, Maria Trojano, et al.
Brain : a Journal of Neurology|October 21, 2017
Towards personalized therapy for multiple sclerosis: prediction of individual treatment responseTomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, et al.
Pageof 27

Showing results (241-250 of 266) with videos related to

Sort By:
Pageof 27
Brain : a Journal of Neurology|September 12, 2015
Defining reliable disability outcomes in multiple sclerosisTomas Kalincik, Gary Cutter, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 6, 2024
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data NetworkJohannes Lorscheider, Alessio Signori, Suvitha Subramaniam, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 28, 2022
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data networkAlessio Signori, Johannes Lorscheider, Sandra Vukusic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 11, 2013
Predictors and dynamics of postpartum relapses in women with multiple sclerosisStella E Hughes, Tim Spelman, Orla M Gray, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2015
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosisMatthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, et al.
Multiple Sclerosis and Related Disorders|August 2, 2022
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-βSteve Simpson-Yap, Ashkan Pirmani, Edward De Brouwer, et al.
Brain : a Journal of Neurology|July 13, 2016
Defining secondary progressive multiple sclerosisJohannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 15, 2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisTomas Kalincik, Eva Kubala Havrdova, Dana Horakova, et al.
Annals of Neurology|October 7, 2014
Seasonal variation of relapse rate in multiple sclerosis is latitude dependentTim Spelman, Orla Gray, Maria Trojano, et al.
Brain : a Journal of Neurology|October 21, 2017
Towards personalized therapy for multiple sclerosis: prediction of individual treatment responseTomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, et al.
Pageof 27